CLVLY and UR9 Related Headlines
Go Back- CLINUVEL implements strategic reorganisation to refocus on U.S. markets
- CLINUVEL’s ADS to commence trading on Nasdaq
- SCENESSE® approved for EPP in Canada
- CLINUVEL receives final EMA scientific advice for pivotal Phase III vitiligo study
- CLINUVEL: advancing peptides for photomedicine and vitiligo care at AAD 2026
- CLINUVEL to advance novel pharmaceutical formulations in preclinical program
- CLINUVEL preparing upgrade of ADR program to Level II, Nasdaq uplist
CLVLY and UR9 Related Press Releases
Go Back- CLINUVEL implements strategic reorganisation to refocus on U.S. markets
- CLINUVEL’s ADS to commence trading on Nasdaq
- SCENESSE® approved for EPP in Canada
- CLINUVEL receives final EMA scientific advice for pivotal Phase III vitiligo study
- CLINUVEL: advancing peptides for photomedicine and vitiligo care at AAD 2026
- CLINUVEL to advance novel pharmaceutical formulations in preclinical program
- CLINUVEL preparing upgrade of ADR program to Level II, Nasdaq uplist

